Invesaro

Stocks Health care BIOE

OTC · Health care

Bio Essence Corp (BIOE)

Bio Essence Corp brought in $2.9M of revenue over the twelve months to June 30, 2026. Net income was $1.5M, a net margin of 52.1%. At June 30, 2026 it held $675 in cash against $56.8K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch BIOE in 60 seconds
Price
$0.18
-0.06% on the day · September 25, 2026
52-week range $0.05 to $0.52
Market cap
$9.8M
Revenue (last 12 months)
$2.9M
Net margin
52.1%

What Bio Essence Corp does

Bio Essence Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker BIOE.

Revenue and profit by year

Revenue
FY21: $958.7K $958.7K FY21FY21: $888K $888K FY21FY22: $621.6K $621.6K FY22FY23: $551.5K $551.5K FY23FY24: $323.9K $323.9K FY24FY25: $1.9M $1.9M FY25
Net income
FY21: -$595.8K -$595.8K FY21FY21: -$647.6K -$647.6K FY21FY22: -$809.7K -$809.7K FY22FY23: -$971.9K -$971.9K FY23FY24: -$1.3M -$1.3M FY24FY25: $896.2K $896.2K FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$1.9M$900K$896.2Kn/an/a
2024$323.9K-$459.4K-$1.3M-$0.03n/a
2023$551.5K-$345.6K-$971.9K-$0.03-$1M
2022$621.6K-$511.1K-$809.7K-$0.03-$707K
2021$888K-$857.5K-$647.6K-$0.03-$1.4M
2021$958.7K-$832.6K-$595.8K-$0.03-$740.1K

Full financial statements: income, balance sheet and cash flow

Next report expected around November 11, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 12, 2025. Not a date the company has announced. See the report calendar

Where BIOE ranks in Health care

Revenue$1.9M
#613 of 742 in Health care · Bottom 17%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Bio Essence Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 14, 2026
    Quarterly report 10-Q · period to June 30, 2026Revenue rose 207% to $794.7K versus the same quarter last year; net income rose 351% to $270.1K.
  2. May 19, 2026
  3. May 15, 2026
    Quarterly report 10-Q · period to March 31, 2026Revenue rose 2,156% to $500.5K versus the same quarter last year; net income of $205.4K versus a net loss of $205.8K.
  4. April 24, 2026
  5. March 27, 2026
    Annual report 10-K · period to December 31, 2025Revenue rose 486% to $1.9M versus the prior year; net income of $896.2K versus a net loss of $1.3M.
  6. January 5, 2026
  7. November 12, 2025
    Quarterly report 10-Q · period to September 30, 2025Revenue rose 1.6% to $136.8K versus the same quarter last year; net income of $13K versus a net loss of $1.2M.
  8. October 17, 2025
  9. August 14, 2025
    Quarterly report 10-Q · period to June 30, 2025Revenue was $259.1K; diluted EPS was $0.00.
  10. May 15, 2025
    Quarterly report 10-Q · period to March 31, 2025Revenue was $22.2K; diluted EPS was -$0.01.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on November 18, 2024. Insider transactions on SEC

All filings on SEC EDGAR

Questions about BIOE

What does Bio Essence Corp do?

Bio Essence Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker BIOE.

Is Bio Essence Corp profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $1.5M on revenue of $2.9M, a net margin of 52.1%.

How much revenue does Bio Essence Corp make?

Over the twelve months to June 30, 2026 Bio Essence Corp reported revenue of $2.9M.

When did Bio Essence Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.

Similar companies

Compare BIOE with

Compare BIOE with any company

Follow BIOE

Get an email when Bio Essence Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow BIOE: get an email when it files

Where the numbers come from

Financial figures are the values Bio Essence Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.